The Top 5 Biosimilar Articles for the Week of August 25

August 29, 2025

Here are the top 5 biosimilar articles for the week of August 25, 2025.

Alvotech Reports Record-Breaking First Half of 2025 Amid Strong Biosimilar Sales

August 27, 2025

Canadian RWE Shows Comparable Outcomes Between Etanercept Biosimilars, Originator

August 26, 2025

Biosimilar Romiplostim Shows Equivalence to Reference Product for Chronic ITP

August 25, 2025

The Top 5 Biosimilar Articles for the Week of August 18

August 22, 2025

BioRationality: How Developers Can Expand Their Monoclonal Antibody Biosimilar Portfolio

March 24th 2025

By Sarfaraz K. Niazi, PhD

Article

Monoclonal antibodies lead biosimilar approvals because of their large market size, well-defined regulatory pathways, and technological feasibility, whereas other biologics encounter development challenges but may see increased adoption as regulatory frameworks advance.

Patients With IBD Maintain Therapy 2 Years Post Switching to Infliximab Biosimilar

March 23rd 2025

By Deana Ferreri, PhD

Article

People with inflammatory bowel disease (IBD) who switched to the infliximab biosimilar CT-P13 had higher treatment persistence (84% and 91%) than those new to infliximab (66% and 53%), with no new safety concerns.

The Top 5 Biosimilar Articles for the Week of March 17

March 21st 2025

By Cameron Santoro

Video

Here are the top 5 biosimilar articles for the week of March 17, 2025.

Smart Tendering Policies Unlock Greater Biosimilar Savings

March 20th 2025

By Skylar Jeremias

Article

Tendering emerged as the most effective strategy for reducing costs and increasing biosimilar uptake in the retail setting, while price-linked discounts and prescribing quotas have shown mixed or uncertain results.

Multiple Switches Between Adalimumab Biosimilar GP2017 and Humira for Psoriasis Maintain Biosimilarity

March 20th 2025

By Cameron Santoro

Article

Patients with moderate to severe plaque psoriasis who switched between the adalimumab biosimilar GP2017 and reference adalimumab did not impact immunogenicity, safety, or efficacy following up to 4 switches between both drugs.

Real-World Data Confirm Safety of Switching Between Ranibizumab Biosimilars

March 19th 2025

By Skylar Jeremias

Article

Patients with diabetic macular edema previously treated with a ranibizumab biosimilar in India experience comparable safety and efficacy after being switched to another ranibizumab biosimilar, demonstrating real-world safety of biosimilar-to-biosimilar switching.

Promising Results for Ustekinumab, Adalimumab Biosimilars Presented at AAD

March 18th 2025

By Skylar Jeremias

Article

Biocon’s ustekinumab biosimilar matched reference ustekinumab in efficacy and safety, while an adalimumab biosimilar proved interchangeable with reference adalimumab, according to posters at the American Academy of Dermatology (AAD) annual meeting.

Review Calls for Path to Global Harmonization of Biosimilar Development Regulations

March 17th 2025

By Skylar Jeremias

Article

Global biosimilar regulatory harmonization will be needed to reduce development costs and improve patient access, despite challenges posed by differing national requirements and regulatory frameworks, according to review authors.

Retina Specialists’ Evolving View on Biosimilars in AMD Treatment

March 16th 2025

By Skylar Jeremias

Article

The introduction of biosimilars in the treatment of age-related macular degeneration (AMD) is raising concerns among physicians about cost-driven mandates and the autonomy to choose the best therapies for their patients, according to Paul Hahn, MD, PhD, FASRS, a retina specialist at NJ Retina.

Comparable Pregnancy and Infant Milestones With Infliximab Biosimilars vs Originator in IBD

March 15th 2025

By Deana Ferreri, PhD

Article

A study evaluating pregnancy outcomes and infant developmental milestones found similar outcomes between pregnant women with inflammatory bowel disease (IBD) who received reference infliximab and those who received a biosimilar.